CO6551754A2 - 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso - Google Patents

7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso

Info

Publication number
CO6551754A2
CO6551754A2 CO12104940A CO12104940A CO6551754A2 CO 6551754 A2 CO6551754 A2 CO 6551754A2 CO 12104940 A CO12104940 A CO 12104940A CO 12104940 A CO12104940 A CO 12104940A CO 6551754 A2 CO6551754 A2 CO 6551754A2
Authority
CO
Colombia
Prior art keywords
bimatoprost
pent
hept
phenyl
hidrixi
Prior art date
Application number
CO12104940A
Other languages
English (en)
Inventor
Gyorgy F Ambrus
Kiomars Karami
Ke Wu
Original Assignee
Allergan Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=43639099&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CO6551754(A2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Allergan Inc filed Critical Allergan Inc
Publication of CO6551754A2 publication Critical patent/CO6551754A2/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/34—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atoms of the carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C405/00—Compounds containing a five-membered ring having two side-chains in ortho position to each other, and having oxygen atoms directly attached to the ring in ortho position to one of the side-chains, one side-chain containing, not directly attached to the ring, a carbon atom having three bonds to hetero atoms with at the most one bond to halogen, and the other side-chain having oxygen atoms attached in gamma-position to the ring, e.g. prostaglandins ; Analogues or derivatives thereof
    • C07C405/0008—Analogues having the carboxyl group in the side-chains replaced by other functional groups
    • C07C405/0041—Analogues having the carboxyl group in the side-chains replaced by other functional groups containing nitrogen
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/16—Amides, e.g. hydroxamic acids
    • A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/557—Eicosanoids, e.g. leukotrienes or prostaglandins
    • A61K31/5575—Eicosanoids, e.g. leukotrienes or prostaglandins having a cyclopentane, e.g. prostaglandin E2, prostaglandin F2-alpha
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A61P27/06—Antiglaucoma agents or miotics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/12—Antihypertensives
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C231/00—Preparation of carboxylic acid amides
    • C07C231/22—Separation; Purification; Stabilisation; Use of additives
    • C07C231/24—Separation; Purification
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/34—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
    • C07C233/35—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/39—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom having the carbon atom of the carboxamide group bound to an acyclic carbon atom of an unsaturated carbon skeleton containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/30—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton being unsaturated and containing rings other than six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2601/00—Systems containing only non-condensed rings
    • C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
    • C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Ophthalmology & Optometry (AREA)
  • Epidemiology (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con las formas cristalinas de 7-[3,5- dihidroxi-2-(3-hidroxi-5-fenil-pent-1-enil)-ciclopentil]-n-etil-hept-5-enamida (bimatoprost) y en particular con una forma cristalina recientemente idenditicada de bimatoprost.
CO12104940A 2009-11-23 2012-06-22 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso CO6551754A2 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US26347109P 2009-11-23 2009-11-23

Publications (1)

Publication Number Publication Date
CO6551754A2 true CO6551754A2 (es) 2012-10-31

Family

ID=43639099

Family Applications (1)

Application Number Title Priority Date Filing Date
CO12104940A CO6551754A2 (es) 2009-11-23 2012-06-22 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso

Country Status (19)

Country Link
US (2) US8629185B2 (es)
EP (1) EP2504313A1 (es)
JP (2) JP5921439B2 (es)
KR (1) KR20120085330A (es)
CN (2) CN102712584B (es)
AU (1) AU2010321831B2 (es)
BR (1) BR112012012387A2 (es)
CA (1) CA2781698A1 (es)
CL (1) CL2012001339A1 (es)
CO (1) CO6551754A2 (es)
HK (1) HK1207570A1 (es)
IL (2) IL219959A (es)
IN (1) IN2012DN05209A (es)
MX (1) MX2012005968A (es)
NZ (1) NZ600263A (es)
RU (1) RU2577546C2 (es)
UA (1) UA110696C2 (es)
WO (1) WO2011063276A1 (es)
ZA (1) ZA201203883B (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2781698A1 (en) * 2009-11-23 2011-05-26 Allergan, Inc. 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof
CA2837261C (en) 2011-06-02 2020-12-15 CHINOIN Zrt. Novel processes for the preparation of prostaglandin amides
EP2911623B1 (en) 2012-10-26 2019-08-14 Forsight Vision5, Inc. Ophthalmic system for sustained release of drug to eye
PL2934510T3 (pl) * 2012-12-19 2021-07-05 Novartis Ag Formulacje inhibitora lfa-1
US9120738B2 (en) * 2012-12-28 2015-09-01 Allergan, Inc. Crystalline forms of bimatoprost acid, methods for preparation, and methods for use thereof
US9447014B2 (en) 2012-12-28 2016-09-20 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form, methods for preparation, and methods for use thereof
US10273206B2 (en) 2014-06-27 2019-04-30 Allergan, Inc. Tromethamine salt of bimatoprost acid in crystalline form 1, methods for preparation, and methods for use thereof
EP3283004A4 (en) 2015-04-13 2018-12-05 Forsight Vision5, Inc. Ocular insert composition of semi-crystalline or crystalline pharmaceutically active agent
CN115677549A (zh) * 2022-10-27 2023-02-03 神隆医药（常熟）有限公司 一种贝美前列素手性异构体的制备方法

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SU403156A3 (es) * 1968-07-29 1973-10-19
US7166730B2 (en) * 2000-01-27 2007-01-23 Fine Tech Laboratories, Ltd Process for the preparation of prostaglandin derivatives
IL143477A (en) * 2001-05-31 2009-07-20 Finetech Pharmaceutical Ltd Process for the preparation of 17-phenyl-18,19,20-trinor-pgf2?? and its derivatives
EP1307191A2 (en) * 2000-07-28 2003-05-07 Inspire Pharmaceuticals, Inc. Use of indole derivatives for the manufacture of a medicament for reducing intracular pressure
CN1922255B (zh) * 2003-12-30 2011-01-19 梅塔博利克斯股份有限公司 成核剂
IL177762A0 (en) * 2006-08-29 2006-12-31 Arieh Gutman Bimatoprost crystalline form i
CA2781698A1 (en) * 2009-11-23 2011-05-26 Allergan, Inc. 7-[3,5-dihydroxy-2-(3-hydroxy-5-phenyl-pent-1-enyl)-cyclopentyl]-n-ethyl-hept-5-enamide (bimatoprost) in crystalline form ii, methods for preparation, and methods for use thereof

Also Published As

Publication number Publication date
US9181176B2 (en) 2015-11-10
BR112012012387A2 (pt) 2019-09-24
CN102712584B (zh) 2014-10-29
EP2504313A1 (en) 2012-10-03
IN2012DN05209A (es) 2015-10-23
KR20120085330A (ko) 2012-07-31
MX2012005968A (es) 2012-08-15
CN104367580A (zh) 2015-02-25
AU2010321831A1 (en) 2012-06-21
AU2010321831B2 (en) 2016-07-07
JP2016094471A (ja) 2016-05-26
CL2012001339A1 (es) 2012-08-10
HK1207570A1 (en) 2016-02-05
WO2011063276A1 (en) 2011-05-26
IL219959A (en) 2015-07-30
IL219959A0 (en) 2012-07-31
JP5921439B2 (ja) 2016-05-24
CN102712584A (zh) 2012-10-03
US20140113974A1 (en) 2014-04-24
JP2013511573A (ja) 2013-04-04
ZA201203883B (en) 2013-01-31
RU2012125185A (ru) 2013-12-27
NZ600263A (en) 2014-08-29
RU2577546C2 (ru) 2016-03-20
US20110152376A1 (en) 2011-06-23
US8629185B2 (en) 2014-01-14
UA110696C2 (uk) 2016-02-10
IL239892A0 (en) 2015-08-31
CA2781698A1 (en) 2011-05-26

Similar Documents

Publication Publication Date Title
CO6551754A2 (es) 7-[3.5-dihidroxi-2-(3-hidrixi-5-fenil-pent-1-enil)- ciclopentil] -n-etil-hept-5-enamida(bimatoprost) en forma cristalina ii, mètodos para la preparaciòn y mètodo para su uso
ECSP078055A (es) Formas sólidas cristalinas de tigeciclina y métodos para preparar las mismas
BR112014025101A2 (pt) composição de geopolímero de aluminossilicato, uso da composição, método para preparar a referida composição e mistura cimentícia para dar forma
AR061311A1 (es) Procesos para preparar clorhidrato de cinacalcet y formas polimorficas del mismo
CR20120011A (es) Inhibidores de bace
AR086586A1 (es) Forma cristalina de ciclosporina a, metodos de preparacion y metodos para utilizar la misma
BR112014000236A2 (pt) lipossomas com razão n:p útil para a liberação de moléculas de rna, composição e uso de ditos lipossomas
BRPI0812481A2 (pt) Composição aquosa, processo para a fabricação da composição aquosa, uso da composição aquosa, e, processo para a produção de epicloridrina
BR112013014598A2 (pt) composição imunogênica, uso de uma composição imunogênica, processo para preparar uma composição imunogênica, método para a fabricação de uma composição imunogênica estável, e, kit
BR112015005404A2 (pt) Formas polimórficas de enzalutamida e sua preparação
BRPI0911815A2 (pt) estrutura de multifilme, estrutura de envelope feita de uma estrutura de multifilme, uso de uma estrutura de multifilme e processo para preparar uma estrutura de multifilme
CR20110576A (es) Anticuerpos anti-egfl7 humanizados y métodos de uso de los mismos
HN2011002408A (es) Nueva forma cristalina vi de la agomelatina, preparacion y uso de la misma.
BR112013001423A2 (pt) método, método in vitro, uso e kit útil para realizar o método
AR074985A1 (es) Bacterias etanologenicas y su uso en la produccion de etanol
BRPI0915092A2 (pt) composição de frutooligossacarídeo, processo para sua produção e uso
CL2009001686A1 (es) Procedimiento de preparacion de agomelatina; y los compuestos intermediarios considerados.
CL2013001716A1 (es) Aleacion de aluminio para fabricar bloques gruesos; su proceso de fabricacion; bloque grueso de aluminio; y uso de dicho bloque para la fabricacion de moldes para inyeccion de plasticos.
CL2012002540A1 (es) Hidrato de hidrocloruro de agomelatina; forma cristalina; metodo de preparacion; composicion farmaceutica ; y su uso para el tratamiento de trastornos del sueño, estrés, ansiedad, depresion mayor, enfermedades cardiovasculares, entre otras.
BRPI1011351A2 (pt) solução, uso de uma solução, terpolímero, processo para preparar terpolímeros,e uso de terpolímeros
AR113695A1 (es) Una d-psicosa 3-epimerasa y el uso de un método para producir d-psicosa
BRPI1008276A2 (pt) processo para a preparação e uso de uma composição
AR080203A1 (es) Formas solidas que comprenden una ciclopropilamida
BR112014001052A2 (pt) método para reduzir a agregação de uma proteína, uso de uma composição polianiônica, composição, e, método e processo para a produção de uma composição
BR112013015903A2 (pt) polimorfo cristalino, processo para preparar um polimorfo, composição farmacêutica, forma purificada do polimorfo, uso de um polimorfo, processo para preparar um composto, e, composto.